Inhibition of interleukin-1β decreases aneurysm formation and progression in a novel model of thoracic aortic aneurysms

Circulation

Volumn 130, Issue 11, 2014, Pages S51-S59

  Johnston, William F ^a   Salmon, Morgan ^a   Pope, Nicolas H ^a   Meher, Akshaya ^a   Su, Gang ^b   Stone, Matthew L ^a   Lu, Guanyi ^b   Owens, Gary K ^c   Upchurch, Gilbert R ^b,c   Ailawadi, Gorav ^a,d  

^a Division of Thoracic and Cardiovascular Surgery   (United States)

^b Division of Vascular and Endovascular Surgery   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d University of Virginia   (United States)

Author keywords

Aneurysm; Animal models of human disease; Inflammation; Interleukin 1; Interleukin 1 receptor antagonist protein

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ELASTASE; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 23; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PANCREATIC ELASTASE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTIC TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG HALF LIFE; FEMALE; GENE DELETION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE CELL; THORACIC AORTA; THORACIC AORTA ANEURYSM; THORACOTOMY; UPREGULATION; ANEURYSM; ANIMAL; ANIMAL MODELS OF HUMAN DISEASE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COMORBIDITY; DISEASE MODEL; DRUG ANTAGONISM; DRUG SCREENING; GENETICS; INFLAMMATION; INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN; KNOCKOUT MOUSE; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANEURYSM; ANIMAL MODELS OF HUMAN DISEASE; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN;

AGED; ANIMALS; AORTIC ANEURYSM, THORACIC; CASPASE 1; COMORBIDITY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PANCREATIC ELASTASE; RECEPTORS, INTERLEUKIN-1; THORACOTOMY;

EID: 84908083590     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.006800     Document Type: Article

References (24)

1. Bickerstaff LK, Pairolero PC, Hollier LH, Melton LJ, Van Peenen HJ, Cherry KJ, Joyce JW, Lie JT. Thoracic aortic aneurysms: a populationbased study. Surgery. 1982;92:1103-1108.
2. Johansson G, Markström U, Swedenborg J. Ruptured thoracic aortic aneurysms: a study of incidence and mortality rates. J Vasc Surg. 1995;21:985-988.
3. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, Elefteriades JA. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73:17-27, discussion 27.
4. Bavaria JE, Appoo JJ, Makaroun MS, Verter J, Yu ZF, Mitchell RS; Gore TAG Investigators. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial. J Thorac Cardiovasc Surg. 2007;133:369-377.
5. Wassef M, Upchurch GR, Jr, Kuivaniemi H, Thompson RW, Tilson MD III. Challenges and opportunities in abdominal aortic aneurysm research. J Vasc Surg. 2007;45:192-198.
6. Ruddy JM, Jones JA, Spinale FG, Ikonomidis JS. Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg. 2008;136:1123-1130.
7. Ailawadi G, Knipp BS, Lu G, Roelofs KJ, Ford JW, Hannawa KK, Bishop K, Thanaporn P, Henke PK, Stanley JC, Upchurch GR, Jr. A nonintrinsic regional basis for increased infrarenal aortic MMP-9 expression and activity. J Vasc Surg. 2003;37:1059-1066.
8. MacSweeney ST, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg. 1994;81:935-941.
9. Theruvath TP, Jones JA, Ikonomidis JS. Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch. J Card Surg. 2012;27:81-90.
10. Dinarello CA. A clinical perspective of IL-1? as the gatekeeper of inflammation. Eur J Immunol. 2011;41:1203-1217.
11. Johnston WF, Salmon M, Su G, Lu G, Stone ML, Zhao Y, Owens GK, Upchurch GR, Jr., Ailawadi G. Genetic and pharmacologic disruption of interleukin-1beta signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2013;33:294-304.
12. Absi TS, Sundt TM, III, Tung WS, Moon M, Lee JK, Damiano RR, Jr, Thompson RW. Altered patterns of gene expression distinguishing ascending aortic aneurysms from abdominal aortic aneurysms: complementary DNA expression profiling in the molecular characterization of aortic disease. J Thorac Cardiovasc Surg. 2003;126:344-357, discission 357.
13. Ikonomidis JS, Gibson WC, Gardner J, Sweterlitsch S, Thompson RP, Mukherjee R, Spinale FG. A murine model of thoracic aortic aneurysms. J Surg Res. 2003;115:157-163.
14. Alexander MR, Murgai M, Moehle CW, Owens GK. Interleukin-1s modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-?B-dependent mechanisms. Physiol Genomics. 2012;44:417-429.
15. Carter DB, Deibel MR, Jr, Dunn CJ, Tomich CS, Laborde AL, Slightom JL, Berger AE, Bienkowski MJ, Sun FF, McEwan RN. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature. 1990;344:633-638.
16. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos PN, Kremastinos DT. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117:2662-2669.
17. Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14, 000 cases from 1987 to 2002. Circulation. 2006;114:2611-2618.
18. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, White MR, Dinarello CA, Apte RN. IL-1a and IL-1s recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 2011;187:4835-4843.
19. Slee EA, Zhu H, Chow SC, MacFarlane M, Nicholson DW, Cohen GM. Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD. FMK) inhibits apoptosis by blocking the processing of CPP32. Biochem J. 1996;315(Pt 1):21-24.
20. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417-426.
21. Wu D, Albini P, Xu G, Xie W, Ren P, Zhang L, Palmero L, Coselli J, Shen Y, LeMaire S. Nlrp3 inflammasome is upregulated in thoracic aortic aneurysms and dissections. J Surg Res. 2012;172:280.
22. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1006-1012.
23. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (cantos). Am Heart J. 2011;162:597-605.
24. Coady MA, Rizzo JA, Hammond GL, Kopf GS, Elefteriades JA. Surgical intervention criteria for thoracic aortic aneurysms: a study of growth rates and complications. Ann Thorac Surg. 1999;67:1922-1926; discussion 1953.